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Abstract: Rifaximin is a broad-spectrum antibiotic that ameliorates symptomatology in inflamma-
tory/functional gastrointestinal disorders. We assessed changes in gut commensal microbiota (GCM)
and Toll-like receptors (TLRs) associated to rifaximin treatment in mice. Adult C57BL/6NCrl mice
were treated (7/14 days) with rifaximin (50/150 mg/mouse/day, PO). Luminal and wall-adhered
ceco-colonic GCM were characterized by fluorescent in situ hybridization (FISH) and microbial pro-
files determined by terminal restriction fragment length polymorphism (T-RFLP). Colonic expression
of TLR2/3/4/5/7 and immune-related markers was assessed (RT-qPCR). Regardless the period of
treatment or the dose, rifaximin did not alter total bacterial counts or bacterial biodiversity. Only a
modest increase in Bacteroides spp. (150 mg/1-week treatment) was detected. In control conditions,
only Clostridium spp. and Bifidobacterium spp. were found attached to the colonic epithelium. Rifax-
imin showed a tendency to favour their adherence after a 1-week, but not 2-week, treatment period.
Minor up-regulation in TLRs expression was observed. Only the 50 mg dose for 1-week led to a
significant increase (by 3-fold) in TLR-4 expression. No changes in the expression of immune-related
markers were observed. Rifaximin, although its antibacterial properties, induces minor changes in
luminal and wall-adhered GCM in healthy mice. Moreover, no modulation of TLRs or local immune
systems was observed. These findings, in normal conditions, do not rule out a modulatory role of
rifaximin in inflammatory and or dysbiotic states of the gut.
Keywords: dysbiosis; gut commensal microbiota; host-bacterial interaction systems; immune mark-
ers; rifaximin; toll-like receptors
1. Introduction
Rifaximin is a semi-synthetic non-absorbable antibiotic derived from rifamycin and
with a broad-spectrum activity against Gram-positive and Gram-negative microorganisms
proposed to act on the gut microenvironment [1,2]. The main advantage of rifaximin over
similar antibiotics is that it is virtually unabsorbable, which minimizes systemic exposure
and adverse events in all patient populations [3]. Rifaximin showed to be effective for a
variety of clinical uses and was initially approved for the treatment of traveler’s diarrhea
caused by noninvasive strains of E. coli [1] and hepatic encephalopathy (due to its inhibition
of ammonia-producing enteric bacteria and consequent reduction of circulating ammonia
in patients with cirrhosis) [4]. Further clinical evidence led to the approval of the use of
rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome (IBS) [5].
Moreover, in the clinical practice, rifaximin is often prescribed for other gastrointestinal
disorders, such as inflammatory bowel disease (IBD), small intestinal bacterial overgrowth
(SIBO), and diverticular disease, because of its theoretical capability to modulate the
intestinal microbiota [6].
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IBS is a chronic, functional gastrointestinal disorder characterized by abdominal
pain/discomfort, associated with altered bowel habits. The etiology of IBS is unknown and
the pathophysiology is complex, heterogeneous, and not well understood. There is evi-
dence for a number of underlying mechanisms, including altered intestinal barrier function,
altered motility, visceral hypersensitivity and, possibly, a chronic, low-grade inflammatory
or immunological response [7–9]. Moreover, interactions between environmental factors,
such psychosocial stress and anxiety, led to the inclusion of brain-gut interactions in the
etiology of the disease [7,8]. During the last years, gut microbiota has also been implicated
in the pathogenesis of IBS. In this sense, some IBS patients have reduced gut microbial
biodiversity [8] and acute enteric infections have been associated to the development of
IBS, the so called post-infectious IBS [10]. Overall, the presence of dysbiosis, temporal
or permanent, has been seen in more than 70% of patients with IBS [8], although great
variability has been observed [11]. Nevertheless, the connection between dysbiosis and IBS
is not completely understood, and a causal relationship has not been demonstrated [11,12].
It is known that gut commensal microbiota (GCM) contributes to maintenance of gastroin-
testinal homeostasis [13]. Therefore, modifying the GCM is a therapeutic approach of
growing interest for IBS. In this context, rifaximin is used to treat SIBO and IBD [14], and, as
mentioned above, was approved for the treatment of diarrhea-predominant IBS [15]. There
is some clinical overlap between IBS and IBD, and some authors consider IBS and IBD
at the two extremes of the same spectrum, being IBS a low-grade IBD without structural
alterations [16]. In any case, dysbiosis seems to be a common finding in IBS and IBD.
Besides its antibacterial effects, pre-clinical evidence suggests that rifaximin might
have anti-inflammatory activity, reducing mucosal inflammation and visceral hypersen-
sitivity and restoring epithelial barrier function [17–20]. Whether or not these effects are
secondary to its microbial actions or are direct, non-microbial-related, is still a matter of
debate. Moreover, direct effects of rifaximin on intestinal epithelial cell physiology, associ-
ated with reductions in bacterial attachment and internalization and epithelial responses to
inflammatory mediators, have also been suggested [19,21,22].
In this study, we assessed the effects of rifaximin on GCM in healthy mice. For this,
we used fluorescence in situ hybridization (FISH) and a terminal restriction fragment
length polymorphism (T-RFLP) analysis to determine rifaximin-induced changes in colonic
luminal and wall adhered bacteria. To determine if changes in GCM might be associated to
the local modulation of host immune-related responses, we also assessed (real-time qPCR)
changes in the expression of toll-like receptors (TLR)-dependent host-bacterial interaction
systems and immune-related markers.
2. Results
2.1. Effects of Rifaximin on Body Weight, Weight of Body Organs and Colonic Histology
Body weight was stable over the treatment period, without treatment-related sig-
nificant changes (Table 1). At necropsy, the relative weight of the liver was slightly, but
significantly reduced in rifaximin-treated animals, in similar proportion regardless the
dose and the duration of treatment (p < 0.05 vs. respective vehicle-treated group). Relative
weight of the spleen, thymus, and adrenal glands were similar across groups, (data not
shown).
At necropsy, no macroscopic alterations were observed in the colon or cecum, irre-
spective of the experimental group considered. Similarly, cecal and colonic content had a
normal consistency in all experimental groups. Colonic and cecal relative weight was simi-
lar across groups (Table 1). Consistent with these observations, no histological alterations
were observed in the colon in rifaximin-treated animals, regardless the treatment time or
dose. In all cases, total histological scores ranged between 0 and 2 (data not shown).
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Vehicle 4 17.6 ± 0.6 −4.6 ± 2.7 23.2 ± 1.7 21.5 ± 0.9
Rifaximin
(50 mg/kg) 6 17.8 ± 0.2 2.7 ± 2.4 21.8 ± 0.8 25.1 ± 2.3
Rifaximin
(150 mg/kg) 5 18.3 ± 0.2 −1.6 ± 1.5 21.3 ± 1.6 25.9 ± 0.9
14-day
Vehicle 4 17.4 ± 0.7 1.9 ± 2.2 21.7 ± 0.2 22.2 ± 0.8
Rifaximin
(50 mg/kg) 6 18.3 ± 0.3 −2.5 ± 2.1 22.9 ± 1.3 23.7 ± 1.9
Rifaximin
(150 mg/kg) 6 18.2 ± 0.2 2.1 ± 1.4 24.5 ± 0.7 21.2 ± 0.9
1 Data represent mean ± SEM of the number of animals indicated (n).
2.2. Effects of Rifaximin on Luminal GCM
In vehicle-treated animals, regardless the duration of treatment, total bacterial counts
within the luminal content (EUB338-probe) oscillated between 2 × 1010 cells/mL and
1.5 × 1011 cells/mL (Figure 1); consistent with previous observations [23–25]. There
was a good coincidence between total bacterial counts assessed by FISH (EUB338-probe)
and DAPI staining (Figure 1). The most abundant bacterial group was Clostridium spp.
(EREC482-probe), being within the order of 1010 cells/mL; followed by Bacteroides spp.
(BAC303-probe) at 109 cells/mL and Verrucobacteria (VER620-probe) at 108 cells/mL. On
the other hand, Lactobacillus/Enterococcus spp. and Bifidobacterium spp. were ranging
between detection levels (106 cells/mLL) and 108–109 cells/mL. Enterobacteria appeared
below or at the threshold of detection levels (Figures 1 and 2).
Total bacterial counts remained stable after the treatment with rifaximin, regard-
less the dose (50 or 150 mg/kg/day) or the duration of treatment considered (7-day or
14-day). Total counts oscillated between 2 × 1010 cells/mL and 7 × 1010 cells/mL and
1.5 × 1010 cells/mL and 1.5 × 1011 cells/mL for the 7-day and 14-day treatment period,
respectively (Figure 1). Assessment of specific bacterial groups showed an increase in
Bacteroides spp. (BAC303-probe) counts after a 7-day treatment period, but not after a
14-day period (Figures 1 and 2). Although not significant, during the 14-day treatment,
a dose-dependent reduction in the proportion of Clostridium spp. (EREC482-probe) was
observed, at the expense of an increase in the relative abundance the other bacterial groups
assessed, particularly Bacteroides spp. (BAC303-probe) (Figure 2).
The ecological characterization of the luminal microbiota was performed with a T-
RFLP analysis. The dendrogram representation of the similarity indexes of the T-RFLP
profiles of the ceco-colonic microbiota did not show a clustering of the different experimen-
tal groups (Figure 3). The number of t-RFs and their size distribution, taken as a measure
of biodiversity, was similar across groups, regardless the dose (50 or 150 mg/kg/day) or
the duration of treatment considered (7-day or 14-day) (p = 0.166; Figure 4).
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Figure 1. Colonic microbiota, as quantified by FISH after a 7-day or a 14-day treatment period with rifaximin. EUB: Total 
bacteria; BAC: Bacteroides spp.; ENT-D: Enterobacteria group; VER: Verrucobacteria group; BIF: Bifidobacterium spp.; LAB: 
Lactobacillus/Enterococcus spp.; EREC: Clostridium spp. cluster XIVa group. Data are media (interquartile range) ± SD, n =4–
6 per group. *: p < 0.05 vs. corresponding vehicle. #: p < 0.05 vs. rifaximin at 50 mg/kg. V: Vehicle; R50: rifaximin at 50 
mg/kg; R150: rifaximin at 150 mg/kg. 
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spp. (BIF), Clostridium spp. (EREC), Enterobacteria (ENT), Lactobacillus spp. (LAB), and Verrucobacteria (VER)]. Relative 
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4–6 per group. V: Vehicle; R50: rifaximin at 50 mg/kg; R150: rifaximin at 150 mg/kg. 
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Figure 2. Relative distribution of the colonic microbiota, as quantified by FISH, in the different experimental groups. Data
represent the relative abundance (percent) of the bacterial groups characterized [Bacteroides spp. (BAC), Bifidobacterium spp.
(BIF), Clostridium spp. (EREC), Enterobacteria (ENT), Lactobacillus spp. (LAB), and Verrucobacteria (VER)]. Relative percent
composition of the microbiota was calcul ted taking as 100% the total coun s of the bacterial groups assessed. n = 4–6 per
group. V: Vehicle; R50: rifaximin at 50 mg/kg; R150: rifaximin at 150 mg/kg.
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Figure 3. Ecological characterization of the luminal microbiota by T-RFLP analysis. Dendrogram 
showing the distribution of the different experimental groups according to the T-RFLP banding 
patterns obtained from the analysis of the ceco-colonic samples. Each line represents an animal 
identified by either R50 (rifaximin at 50 mg/kg), R150 (rifaximin at 150 mg/kg) or V (vehicle), fol-
lowed by the experimental period (7-day or 14-day). The dendrogram distances represent percent-
age of similarity. The different experimental groups did not cluster together indicating the absence 
of treatment-related changes in the microbiota composition. 
 
Figure 4. Ecological characterization of the luminal microbiota by T-RFLP analysis: Effects of rifax-
imin on biodiversity of the ceco-colonic microbiota. (A) Number of tRFs detected. Each symbol 
represents an individual animal; the horizontal lines with errors correspond to the mean ± SEM. 
For the sake of clarity, and since no differences were observed among them, vehicle-treated ani-
mals have been merged in a single group. V: Vehicle; R50: rifaximin at 50 mg/kg; R150: rifaximin 
at 150 mg/kg. (B) Distribution of the tRFs detected according to their size. Each line represents an 
individual animal and each column a tRF size. tRF distribution indicates a similar microbial biodi-
versity in all experimental groups, regardless the treatment applied. See also Table 2 for details 
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Figure 4. Ecological characterization of the luminal microbio a by T-RFLP analysis: Effec s of rifaximin on biodiversi y f
the ceco-colonic microbiota. (A) Number of tRFs detected. Each sy bol represents an individual animal; the horizontal
lines with errors correspond to the mean ± SEM. For the sake of clarity, and since no differences were observed among
them, vehicle-treated animals have been merged in a single group. V: Vehicle; R50: rifaximin at 50 mg/kg; R150: rifaximin
at 150 mg/kg. (B) Distribution of the tRFs detected according to their size. Each line represents an individual animal and
each column a tRF size. tRF distribution indicates a similar microbial biodiversity in all experimental groups, regardless the
treatment applied. See also Table 2 for details regarding taxonomical classification of the tRFs detected.
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Table 2. Theoretical restriction 5′-fragment (tRF) size predicted for the major mouse gut bacteria and prevalence in the
different experimental groups.














Unidentified 54–55 3 (75) 4 (100) 4 (67) 3 (50) 3 (60) 5 (83)
Bacillus spp./Lactococcus lactis spp. 61–62 1 (25) 2 (50) 1 (17) 0 (0) 1 (20) 1 (17)




67 0 (0) 0 (0) 0 (0) 0 (0) 1 (20) 1 (17)
Mycobacterium spp./
uncultured rumen bacterium 68 0 (0) 2 (50) 1 (17) 2 (33) 1 (20) 2 (33)
Uncultured rumen bacterium 69 4 (100) 4 (100) 5 (83) 5 (83) 4 (80) 6 (100)
Uncultured rumen bacterium/
Leptotrichia spp. 71 2 (50) 1 (25) 4 (67) 1 (17) 2 (40) 0 (0)
Uncultured rumen bacterium 72 1 (25) 1 (25) 1 (17) 3 (50) 2 (40) 1 (17)
Photorhabdus sp. 74–75 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Uncultured bacterium 77 2 (50) 1 (25) 3 (50) 3 (50) 1 (20) 5 (83)
Uncultured rumen bacterium/
naphthalene-utilizing bacterium 78 1 (25) 3 (75) 1 (17) 1 (17) 1 (20) 3 (50)
Uncultured bacterium 80 1 (25) 0 (0) 2 (33) 0 (0) 1 (20) 0 (0)
Sphingomonas spp./
uncultured bacterium 81 0 (0) 1 (25) 0 (0) 0 (0) 0 (0) 0 (0)
Uncultured bacterium 84 3 (75) 2 (50) 2 (33) 1 (17) 0 (0) 1 (17)
Desulfovibriodefluvii/
Roseiflexus spp. 86–87 2 (50) 1 (25) 1 (17) 2 (33) 1 (20) 5 (83)
Flavobacterium psychrophilum 88–89 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17)
Flavobacterium johnsoniae 90 1 (25) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Anaeromyxobacter dehalogenans/










93–94 2 (50) 0 (0) 3 (50) 4 (67) 2 (40) 5 (83)
Desulfovibrio profundus/
uncultured bacterium 95 2 (50) 0 (0) 3 (50) 1 (17) 1 (20) 0 (0)




97–98 1 (25) 0 (0) 4 (67) 4 (67) 2 (40) 4 (67)
Helicobacter pylori/
uncultured rumen bacterium 99 2 (50) 1 (17) 2 (33) 1 (20) 5 (83)
Bacteroides spp./




101–102 1 (25) 2 (50) 0 (0) 0 (0) 0 (0) 0 (0)
Uncultured rumen bacterium 103–104 1 (25) 1 (25) 1 (17) 0 (0) 0 (0) 0 (0)
Uncultured bacterium 105 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Desulfitobacterium hafniense 107–108 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Thiobacillus spp. 110–111 1 (25) 2 (50) 0 (0) 0 (0) 1 (20) 0 (0)
Uncultured bacterium 112 0 (0) 1 (25) 0 (0) 1 (17) 0 (0) 0 (0)
Unidentified 113 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 1 (17)
Uncultured bacterium 116 2 (50) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unidentified 117 1 (25) 2 (50) 4 (67) 3 (50) 2 (40) 5 (83)
Desulfitobacterium hafniense 118 1 (25) 0 (0) 2 (33) 1 (17) 1 (20) 0 (0)
Unidentified 123–124 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Unidentified 127–129 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Unidentified 136 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Uncultured rumen bacterium 137 1 (25) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Microbacterium spp. 144–145 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Leucobacter spp./
Janibacter spp. 147 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
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Unidentified 148–149 0 (0) 0 (0) 2 (33) 0 (0) 1 (20) 0 (0)
Pseudomonas aeruginosa 155 0 (0) 0 (0) 0 (0) 1 (17) 1 (20) 1 (17)
Unidentified 156 1 (25) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Unidentified 163 0 (0) 0 (0) 0 (0) 1 (17) 1 (20) 1 (17)
Synechococcus spp. 164 1 (25) 0 (0) 0 (0) 3 (50) 0 (0) 0 (0)
Unidentified 165–167 0 (0) 0 (0) 3 (50) 0 (0) 1 (20) 0 (0)
Uncultured bacterium 178 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Uncultured rumen bacterium 179 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 1 (17)
Uncultured rumen bacterium 180 0 (0) 0 (0) 0 (0) 2 (33) 0 (0) 0 (0)
Uncultured rumen bacterium 181–182 1 (25) 0 (0) 2 (33) 2 (33) 0 (0) 0 (0)
Uncultured rumen bacterium 183 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Uncultured rumen bacterium 184–185 1 (25) 0 (0) 2 (33) 0 (0) 1 (20) 0 (0)
Listeria monocytogenes 186 1 (25) 0 (0) 0 (0) 0 (0) 1 (20) 0 (0)
Uncultured rumen bacterium 187 1 (25) 0 (0) 1 (17) 0 (0) 1 (20) 1 (17)




194–195 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unidentified 199 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)








202 0 (0) 0 (0) 0 (0) 0 (0) 1 (20) 0 (0)
Uncultured rumen bacterium 203–204 2 (50) 1 (25) 3 (50) 1 (17) 1 (20) 5 (83)
Clostridium spp. 231–232 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0)
Clostridium perfringens 234–235 0 (0) 0 (0) 1 (17) 0 (0) 1 (20) 1 (17)
Clostridium botulinum 237 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 1 (17)




241–242 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Geobacillus






356 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Microbispora spp./





358 0 (0) 0 (0) 2 (33) 2 (33) 0 (0) 1 (17)
Arthrobacter spp. 359 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 1 (17)
Uncultured bacterium 500 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17)
1 Data represent the number of animals within each group presenting the bacterial group predicted by the corresponding tRF size and the
incidence, in percentage (between brackets).
Table 2 summarizes the main bacterial groups, as detected by the T-RFLP analysis,
with differential presence in the six experimental groups (see also Figure 4B for distribution
of the different tRF detected in function of their size). Overall, the T-RFLP analysis reveals
high similarities in bacterial composition among the different experimental groups, without
evident dose- or period of treatment-related changes in the diversity of the microbiota.
Although similar bacterial groups were detected (according to the theoretical restriction
5′-fragment size), in many cases these groups could not be identified phylogenetically and
were classified as “unidentified” or “uncultured bacterium”. According to the T-RFLP, tRFs
with a size between 356 and 359 appeared in some rifaximin-treated animals, regardless
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the dose or the duration of treatment (Figure 4B). Although this might indicate some
treatment-related effect, the low incidence observed (17–33%; Table 2) complicates its
interpretation.
2.3. Effects of Rifaximin on Bacterial Adherence to the Colonic Wall
In vehicle-treated mice, Bifidobacterium spp. and Clostridium spp. were the only bacte-
rial group attached to the colonic wall (epithelium). The overall incidence of attachment
ranged from 12.5 to 37.5% (Figures 5 and 6).
Figure 5. Bacterial wall adherence. Representative images (×100) showing bacterial adherence to the
colonic epithelium for Bifidobacterium spp. and Clostridium spp. (A,A’) non-adhered bacteria within
the intestinal lumen. (B,B’) adhered bacteria in a vehicle-treated mice (7-day), (C,C’) adhered bacteria
in a rifaximin-treated mice (50 mg/kg, 7-day); (D,D’) adhered bacteria in a rifaximin-treated mice
(150 mg/kg, 7-day).
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During antibiotic treatment for a 7-day period, there was a tendency to increase the
incidence of bacterial wall adherence for Clostridium spp. (from an incidence of 37.5% in con-
trol conditions to 50 and 75% at 50 mg/kg and 150 mg/kg, respectively) and Bifidobacterium
spp. (from an incidence of 12.5% in control conditions to 50% for both antibiotic-treated
groups). However, this tendency disappeared in animals treated for a 14-day period
(Figures 5 and 6).
2.4. Effects of Rifaximin on Colonic Expression of TLRs and Immune-Related Markers
Expression of TLR2, 3, 4, 5 and 7 was detected in all colonic samples. Overall, rifax-
imin induced minor changes in TLRs expression with only a moderate (2- to 3-fold), but
significant, up-regulation observed for TLR3 and 4 for the 50 mg/kg dose during a 7-day
period (Figure 7).
Expression of all immune-related markers assessed was detected in colonic tissues,
although in some cases with relatively high variability. Regardless the dose and time of
treatment, no changes were observed for pro-inflammatory cytokines (IL-6, IL-18, IFNγ and
IL-12p40), anti-inflammatory cytokines (IL-10) or antimicrobial peptides (Defα24, RELMβ
and RegIIIγ) (Figure 8).
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ti i tic rifaxi in on C in healthy mice. Overall, rifaximin did not alter the home-
ostatic s ate of the gastroin estinal tract xpected in healthy animal . Results obtained
show that rifax min did not le d to major altera ions n the mi robial ec system of the
gastrointestinal tract. Fu thermore, rifaximin did not affect the local (colonic) expression of
different immune-related markers associated to host-b cterial interactions.
The main focus of this study was on the ceco-colonic microbiota, since this region
represents the largest proportion of the total gut microbiota and is also used to characterize
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dysbiosis in IBS and IBD [11]. Even though rifaximin has broad-spectrum activity against
aerobic and anaerobic Gram-positive and Gram-negative bacteria, we show that during
rifaximin treatment the GCM of standard, healthy mice was essentially not affected. Total
bacterial counts in vehicle-treated mice were in the range previously described [24,26]
and were not altered after a 7-day or a 14-day treatment with the antibiotic. In agreement
with this, bacterial biodiversity, as assessed by a T-RFLP analysis, was not affected by
rifaximin. This is consistent with previous studies showing no changes in total fecal
bacterial counts after rifaximin treatment in patients with intestinal inflammation [2,27]
or diarrheal disease [28] or in pre-clinical models [29]. However, these results contrast
with data showing reductions in total fecal bacterial counts in rats after a 3-day treatment
period at similar doses to those used here [30] or in ileal bacterial load in rats subjected to
psychological stress [18,31]. These apparent discrepancies might reflect species-, treatment
protocol- or disease state-related differences. Alternatively, a lack of changes might be
related to a fast resilience-like response in which a quick adaptation and recovery of the
microbiota might occur; since, comparatively, higher changes were observed after a 7-day
vs. a 14-day treatment period.
A lack of effects of rifaximin inducing a clear dysbiosis in the present experimental
conditions, against its expected antimicrobial effects and compared to other antibiotic
treatments [23,32,33], might suggest a lack of efficacy of the treatment applied. However,
the doses tested are in the range of those used in other reports showing biological activ-
ity [18,30,31,33]. Moreover, it does not seem related to a loss of activity of the antibiotic
since in vitro testing using classical microbiological culture procedures showed efficacy
against S. aureus and E. coli (data not shown).
Although without overall effects in total bacterial counts, rifaximin has been sug-
gested to modulate the composition of the microbiota [2,19,27,34,35]. To assess this, we
determined changes in specific ceco-colonic bacterial groups that are recognized as either
beneficial (such as lactic acid bacteria like Lactobacillus/Enterococcus spp., and Bifidobac-
terium spp.) or harmful bacteria (such as some groups of Clostridium spp., Bacteroides spp.,
and Enterobacteria) [36]. The only bacterial group affected by rifaximin was Bacteroides spp.,
whose presence was favored by the antibiotic during the 7-day treatment, with a similar
tendency observed during the 14-day treatment period. This is in agreement with recent
studies in a murine model of ankylosing spondylitis in which rifaximin treatment increased
the population of Bacteroidetes [34]. However, it contrasts with previous results showing
exclusively an increase in Bifidobacterium spp. counts after a treatment with rifaximin [2,27].
Again, these contradictory results might be related to differences in the experimental con-
ditions and/or reflect species related-differences (human vs. rodent). Composition of
GCM is different in humans and rodents and differs significantly among rodent strains
depending upon their breeder and their housing conditions [24,37]. For instance, rifaximin
treatment also failed to affect microbiota in mice with a humanized microbiota [38], further
emphasizing the importance of species-related aspects when assessing the microbiota.
The exact mechanisms by which rifaximin improves disease symptoms in IBD, IBS
or diarrheic disease remain largely unknown [19]. In agreement with the limited effects
of rifaximin in intestinal microbiota (in either normal or dysbiotic conditions) evidences
suggest the existence of antibiotic-independent effects, likely modulating the local immune
environment within the gastrointestinal tract as well as having direct effects on intestinal
epithelial cells, modulating bacterial attachment and internalization and inhibiting intesti-
nal bacterial translocation [19,21,22]. In this sense, changes in host–bacterial interaction,
through the modulation of bacterial wall adherence, represent an attractive alternative
mechanism of action, since only epithelium-attached bacteria are able to signal to the host
leading to immune-related responses [19,39,40]. In our conditions, bacterial attachment
to the colonic epithelium, as assessed by FISH of tissue samples from the colon, was only
occasionally observed in control animals. In particular, only Clostridia and Bifidobacteria,
including harmful and beneficial bacteria, respectively, were found attached to the colonic
epithelium. Treatment with rifaximin did not affect this pattern, although a slight, and
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parallel, tendency to increase the incidence of attachment was observed for both bacterial
groups during the 7-day treatment; with a progression towards control values for the 14-
day treatment groups. The fact that rifaximin seems to promote the adherence of beneficial
commensal bacteria at the same time than pathogenic microorganisms may contribute to its
beneficial effects in the treatment of SIBO. In these conditions, the balance between negative
and positive signals mediated through the interactions with harmful and beneficial bacteria,
respectively, might inhibit dysbiosis-associated negative responses in the host, promoting
the restoration of intestinal homeostasis, including a state of normobiosis.
Some evidences also suggest direct effects of rifaximin on intestinal epithelial cells,
likely modulating local immune responses. To evaluate this possibility, we also assessed
potential changes in the expression of local (colonic) immune-related markers during ri-
faximin treatment. In particular, we assessed the expression of TLR2, 3, 4, 5 and 7 and
antimicrobial peptides (Defα24, RELMβ and RegIIIγ), according to their high expression
within the gastrointestinal tract [40] and their implication in states of dysbiosis [41–43] as
well as pro- (IL-6, INFγ, IL-18, IL-12p40) and anti-inflammatory cytokines (IL-10), impli-
cated in the development of colitis [44]. Overall, no significant changes were observed in the
expression of cytokines, either pro- or anti-inflammatory, antimicrobial peptides or TLRs.
In fact, only a moderate up-regulation was observed for TLR3 and TLR4 (50 mg, 7-day
treatment). Few studies have addressed the effects of rifaximin on immune-related markers
in control/healthy conditions. In this respect, no effects on inflammatory mediators after
rifaximin treatment were observed in healthy animals treated with the antibiotic [17,30].
In states of altered gut function or chronic systemic inflammatory conditions (implicating
also the gastrointestinal tract) both anti-inflammatory activity [34] and no effects on in-
flammation within the gut [17,38] have been reported for rifaximin. Similarly, Yang et al.
(2019) [34] reported only a moderate down-regulation of intestinal TLR4 in a murine model
of ankylosing spondylitis. Altogether, additional studies in control conditions (healthy
animals) as well as in pathophysiological states involving the gastrointestinal tract are
necessary to fully understand the direct, antibacterial-independent, effects of rifaximin
on gastrointestinal immune responses. In our study, rifaximin was tested in standard,
healthy animals, so we cannot exclude the possibility that the antibiotic might have a more
pronounced effects in a disease-state model. This hypothesis warrants further follow-up
studies. Moreover, additional studies confirming the current observation at the protein
level (i.e., immunohistochemistry and/or Western blot) should also be performed.
As mentioned, several studies showed that antibiotic treatment in normal animals
lead to a state dysbiosis concomitant to an immune activation, the induction of intestinal
inflammation and the modulation of visceral sensory-related systems [23,32,33,45]. In
our case, no evidence of immune activation or colonic alterations consistent with the
development of an inflammatory-like state was observed upon macroscopic or microscopic
examination of the colon. These differences are likely due to differences in the antibiotics
used and their mechanism of action (including potential antimicrobial-independent effects,
as discussed above). Nevertheless, additional, extended immune-related, including the flux
of myeloid cells, as well as epithelial barrier function-related markers should be assessed
in follow-up studies.
In summary, our results show that rifaximin, even though its antibacterial properties,
induces very minor changes in GCM and bacterial wall adherence in normal mice, without
changes in local immune-related markers. Although these observations, more noticeable
effects of rifaximin on dysbiotic states, vs. a normal GCM, cannot be excluded. Therefore,
further studies in dysbiotic animals should be performed to fully assess the effects and
mechanism(s) of action of rifaximin within the gastrointestinal tract in order to fully under-
stand the beneficial effects of the antibiotic in functional and inflammatory gastrointestinal
disorders. These studies should include a broad assessment of immune-related markers
and a deep characterization of the microbiota, including a metabolomics profiling, in order
to detect minor, but functionally significant, changes within the microbiome.
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4. Materials and Methods
4.1. Animals
Female C57BL/6NCrl mice (n = 31), 6 weeks old upon arrival, were obtained from
Charles River Laboratories (Lyon, France). All animals were group-housed (2–4 animals
per cage) under controlled temperature (20–22 ◦C) and photoperiod (12:12 h light-dark
cycle) and had unrestricted access to standard mouse chow and tap water. Mice were
allowed to acclimatize to these conditions for a 1-week period prior to any experimentation.
The experiment was replicated twice at different time points. Females were used accord-
ing to the higher prevalence of functional and inflammatory gastrointestinal disorders in
women [46,47]. All procedures were approved by the Ethical Committee of the Univer-
sitatAutònoma de Barcelona (protocols 1099 and 1101) and the Generalitat de Catalunya
(protocols 5645 and 5646).
4.2. Antibiotic
Rifaximin [4-Deoxy-4′-methylpyrido(1′,2′-1,2)imidazo(5,4-c)rifamycin SV; reference:
R9904, CAS Number 80621-81-4; Sigma-Aldrich, St. Louis, MO, USA] was suspended,
under sonication, in sterile PBS at a final concentration of 50 mg/mL, then aliquoted and
frozen (−20 ◦C) until use. Subsequent dilutions to obtain the desired concentrations were
freshly made, on a daily basis, using sterile PBS. Sterile PBS was used as vehicle control.
4.3. Experimental Protocols
Upon arrival, mice were randomly divided into 6 experimental groups: (i) vehicle,
7-day treatment (n = 4); (ii) rifaximin, 7-day treatment at 50 mg/kg (n = 6); (iii) rifaximin,
7-day treatment at 150 mg/kg (n = 5); (iv) vehicle, 14-day treatment (n = 4); (v) rifaximin,
14-day treatment at 50 mg/kg (n = 6); (vi) rifaximin, 14 day-treatment at 150 mg/kg (n = 6).
Animals were dosed by oral gavage (0.2 mL/mice/day) with either sterile PBS (vehicle) or
the appropriate dose of rifaximin. All treatments were performed in the morning, between
8:00 and 10:00 AM; during 7 or 14 consecutive days depending upon the experimental
group considered. At the time of dosing animals were also weighed. Animals were
euthanized for samples extraction (see below) 24 h after the last treatment. Doses and
duration of treatments were selected in agreement with previous reports addressing effects
of rifaximin and antibiotic-induced dysbiosis in similar experimental conditions [18,22,30].
4.4. Samples Collection
Twenty-four hours after the last treatment animals were deeply anesthetized with
isoflurane (Isoflo, Esteve, Barcelona, Spain) and euthanized by exsanguination through
intracardiac puncture, followed by cervical dislocation. A laparotomy was performed
and fecal samples from the ceco-colonic region obtained and frozen immediately in liquid
nitrogen. All fecal samples were stored at −80 ◦C until analysis.
Thereafter, the cecum, colon, liver, spleen, thymus and adrenal glands were dissected
and weighed. Tissue samples from the colon were fixed overnight in 4% paraformaldehyde
or in Carnoy fixative (ethanol:chloroform:glacial acetic acid, 6:3:1, v:v:v) for histological
studies. After fixing, tissues were paraffin embedded and 5 µm-tick sections obtained for
either Hematoxylin-Eosin staining (4% paraformaldehyde-fixed tissues) or FISH (Carnoy-
fixed tissues).
4.5. Histological Evaluation
For histological examination, hematoxylin-eosin-stained sections from the colon were
obtained following standard procedures. Colonic histology was assessed following, with
minor modifications, procedures previously described by us [23]. A histopathological
score (ranging from 0, normal, to 12, maximal alterations) was assigned to each animal.
Specifically, parameters scored included: epithelial structure (0: normal; 1: mild alterations
of the epithelium; 2: local epithelial damage and/or fusion; 3: generalizedepithelial
damage), structure of the crypts (0: normal; 1: mild alterations of the crypts; 2: local
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damage of the crypts; 3: generalized damage of the crypts), presence of edema (0: normal;
1: mild local edema in submucosa and/or lamina propria; 2: moderate diffuse edema in
submucosa and/or lamina propria; 3: severe generalized edema in submucosa and/or
lamina propria), presence of inflammatory infiltrate (0: normal; 1: mild localized infiltrate;
2: mild generalized infiltrate; 3: severe generalized infiltrate). Scoring was performed on
coded slides by two independent researchers (MF and VM).
4.6. Bacterial Identification by Fluorescence in Situ Hybridization (FISH)
For FISH, previously characterized, bacterial-specific oligonucleotide probes consisted
in a single strain DNA covalently linked with a Cy3 (carbocyanine) reactive fluorescent
dye at the 5′ end (Biomers, Ulm/Donau, Germany and TibMolbiol, Mannheim, Germany)
[23,24,32,48]. The bacterial groups characterized and the specific probes used are indicated
in Table 3.
Table 3. Probes used for FISH and hybridization conditions.




EUB338 GCTGCCTCCCGTAGGAGT All bacteria 50
NON338 ACATCCTACGGGAGGC Non bacteria(negative control) 50
BAC303 CCAATGTGGGGGACCTT Bacteroides spp. 48
EREC482 GCTTCTTAGTCAGGTACCG Clostridiumcoccoidescluster XIVa 50
LAB158 GGTATTAGCACCTGTTTCCA Lactobacillus-Enterococcus spp. 50
90 min,
37 ◦C
ENT-D TGCTCTCGCGAGGTCGCTTCTCTT Enterobacteria 50
VER620 ATGTGCCGTCCGCGGGTT Verrucobacteria 50 30%
BIF164 CATCCGGCATTACCACCC Bifidobacterium spp. 50
For the assessment of luminal bacteria by FISH previously published methods, with
minor modifications, were followed [23,24,32,37,48]. Frozen fecal samples were thawed
and 0.5 g of feces suspended in 4.5 mLof sterile and filtered PBS, including 2–4 glass beads
(diameter 3 mm), and homogenized on a vortex mixer for 3 min. The fecal suspension was
then centrifuged (1 min, 700 g, 4 ◦C) in order to remove large particles from the suspension.
From the supernatant 0.5 µLwere collected and fixed in 1.5 mL freshly prepared 4% filtered
paraformaldehyde solution. After overnight fixing at 4 ◦C, samples were aliquoted (6
portions of 200 µL and 2 portions of 400 µL) and stored at −20 ◦C until use. After thawing,
fixed fecal samples were diluted in sterile and filtered PBS. Dilutions used were: 1600×
and 800× for the EUB338-probe; 400× and 160× for the VER620-, EREC482- and BAC303-
probes; 160× and 80× for the LAB158-probe; 40× and 80× for the BIF164- and ENT-D-
probes. Ten-well slides with round-shaped wells (7 mm diameter) were used. In order to
enhance adhesion of fecal bacteria to the slide, slides were pre-treated by soaking them in a
gelatin-suspension 2% (5 mL: 0.1 g gelatin, 0.01 g KCr(SO4)·12H2O and miliQ water up
to 100 mL) for 30 min and allowed to dry at room temperature. Subsequently, 5 µL of the
proper dilution was pipetted in each separate well. After drying at room temperature, the
slides were fixed for 10 min using 96% ethanol (v/v). Dilutions of the probe were made in TE
Buffer (10 mMTris, 1 mM EDTA; Ambion, Austin, TX, USA) to a concentration of 50 ng/µL
and then stored at −20 ◦C. Prior to use, the diluted probe solutions were further diluted in
hybridization buffer (20 mM Tris–HCl, 0.9 M NaCl, 0.1% SDS, pH 7.2) to a concentration
of 10 ng/µL and preheated at the corresponding temperature (see Table 3). Samples
were hybridized in a dark moist chamber for 3 h by addition of the corresponding Cy3-
labeled oligonucleotide probe. Treatments with formamide or lysozyme and hybridization
temperatures were used as described, to achieve the optimal stringency (see Table 3
for details of hybridization conditions) [23,24,32,37,48,49]. Subsequently, the slides were
rinsed in preheated washing buffer (20 mM Tris–HCl, 0.9 M NaCl, pH 7.2) for 30 min at
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the corresponding temperature (see Table 3). After briefly rinsing in milli-Q, the slides
were air-dried and mounted with Vectashield-DAPI (Vector Laboratories, Peterborough,
UK) on each well and a coverslip. The fluorescent stain 4′,6-diamidino-2-phenylindole
(DAPI), which binds strongly to DNA, served as a control signal in all samples. Hybridized
slides were viewed under oil immersion, using a Carl Zeiss Axioskop 40 FL epifluorescence
microscope (filter for Cy3) equipped with a digital camera (Zeiss AxioCamMRm) for
obtaining digital images (Zeiss AxioVision Release 4.8.1) (Carl Zeiss, Jena, Germany). For
quantification of bacteria, 20 randomly selected fields were photographed, the number of
hybridized cells counted using the CellC software [50], and the mean value obtained. All
procedures were performed on coded slides, to avoid bias.
To assess wall-adhered bacteria, hybridization of tissue samples was also performed.
Sections from Carnoy-fixed paraffin-embedded tissues were deparaffinized, rehydrated,
post-fixed in 4% paraformaldehyde and washed. Hybridization conditions used were
essentially as described above for luminal bacteria (see Table 3 for hybridization conditions),
but in this case tissue samples were incubated for 16 h with the mix of hybridization buffer
and the specific probe. In hybridized tissue samples, 20 randomly selected fields were
photographed. Analysis of the images was performedmanually by two independent
researchers (MF and VM) that observed the pictures and localizedhybridized bacteria
within the mucus layer or attached to the epithelial surface. A coincidence between the
two observers in bacterial location in at least 3 out of the 20 pictures observed (15%) was
required to decide that there was bacterial attachment to the epithelium [23,24,32]. All
procedures wereperformed on coded slides, to avoid bias.
4.7. Terminal Restriction Fragment Length Polymorphism
Terminal restriction fragment length polymorphism (T-RFLP) analysis of bacterial com-
munities was performed following methods published elsewhere [37,51]. Briefly, a 1497-pb
fragment of the 16S rDNA gene was amplified using a 6-carboxy-fluorescein-labeled for-
ward and reverse primers (S-D-Bact-0008-a-S-20: 5′-6-FAM-AGAGTTTGATCMTGGCTCAG-
3′; PH1552: 5′AAGGAGGTGATCCAGCCGCA-3′, respectively) against the first 20 bases
of the 16S RNA sequence. Duplicate PCR were performed for each sample. Fluorescent-
labeled PCR products were purified on QIAquick PCR purification kit columns (Qiagen,
West Sussex, UK) and eluted in a final volume of 30µL of Milli-Q water. Then, the resultant
PCR product was subjected to a restriction with HhaI (20,000 U/µL) (Biolabs Inc., Ipswich,
MA, USA). Fluorescent-labeled terminal restriction fragments (TRF) were analyzed by
capillary electrophoresis on an automatic sequence analyzer (ABI 3100 Genetic Analyzer,
PE Biosystems, Warrington, UK) in Gene-Scan mode with a 25-U detection threshold. De-
termination of the TRF sizes in the range 50–700 bp were performed with the size standard
GS-1000-ROX (PE Biosystems).
Data obtained consisted of size (base pairs) and peak area for each TRF. To standardize
the DNA loaded on the capillary, the sum of all TRF peak areas in the pattern was used to
normalize the peak detection threshold in each sample. Following the method described
by Kitts [52], a new threshold value was obtained by multiplying a pattern’s relative DNA
ratio (the ratio of total peak area in the pattern to the total area in the sample with the
smallest total peak area) by 323 area units (the area of the smallest peak at the 25 detection
threshold in the sample with the smallest total peak area). For each sample, peaks with a
lower area were deleted from the data set. Thereafter, a new total area was obtained by the
sum of all the remaining peak areas in each pattern.
Biodiversity (also known as richness) was considered as the number of peaks in each
sample after standardization. For pair-wise comparisons of the profiles, a Dice coefficient
was calculated, and dendrograms were constructed using the Fingerprinting II software
(Informatix, Bio-Rad, Hercules, CA, USA) and an unweighted pair-group method with
averaging algorithm. To deduce the potential bacterial composition of the samples, in
silico restrictions for the major mouse gut bacteria with the primers and the enzyme used
were obtained by using the analysis function TAP–T-RFLP from the Ribosomal Database
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Project II software. Results are presented as potential compatible bacterial species. Note
also that direct attribution of species to individual peaks is not unequivocally possible
unless fingerprinting is complemented with sequence analysis of clone libraries. Analysis
of electropherograms was used for the visual comparison of compatible TRF with different
bacteria for the different experimental groups.
4.8. Colonic Expression of TLRs and Immune-Related Markers Using Quantitative Real-Time PCR
(RT-qPCR)
Total RNA was extracted from colonic tissue samples using Tri reagent with Ribopure
Kit (Ambion/Applied biosystems, Foster City, CA, USA). RNA samples were converted
into cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
cDNA concentration was measured using NanoDrop (ND-1000 spectrophotometer, Nan-
oDrop Technologies, Wilmington, DE, USA) and all the samples were diluted at 100 ng/µl
with DEPC-Treated water (Ambion/Applied biosystems, Foster City, CA, USA). TaqMan
gene expression assays for interleukin 6 (IL-6) (Mm00446190_m1), interferon gamma (IFNγ)
Mm01168134_m1, interleukin-12 p40 (IL-12p40) (Mm00434174_m1), interleukin-10 (IL-10)
(Mm00439614_m1), interleukin 18 (IL-18) (Mm00434225_m1), defensin alpha 24 (Defα24)
(Mm04205950_gH), resistin-like molecule-β (RELMβ) (Mm00445845_m1), regenerating
islet-derived protein 3 gamma (RegIIIγ) (Mm00441127_m1) and TLR2 (Mm00442346_m),
TLR3 (Mm01207404_m1), TLR4 (Mm00445273_m1), TLR5 (Mm00546288_s1) and TLR7
(Mm00446590_m1) were used (Applied Biosystems). All samples, as well as the negative
controls, were assayed in triplicates. β-2-microglobulin (β2m) (Mm00437762_m1) was used
as endogenous control.
The PCR reaction mixture was incubated on the Bio-Rad CFX384 (Bio-Rad Laborato-
ries). Bio-Rad CFX Manager 3.1 software was used to obtain the cycle threshold for each
sample. All data was analyzed with the comparative Ct method (2-∆∆Ct) with the vehicle
groups serving as calibrator [53].
4.9. Statistical Analysis
Data are expressed as mean ± SEM or media (interquartile range) ± SD, as indicated.
A robust analysis (one iteration) was used to obtain mean ± SEM for RT-qPCR data. Data
were analyzed by one-way analysis of variance (ANOVA), followed, when necessary, by
a Student-Newman-Keuls multiple comparisons test. Data were considered statistically
significant when p < 0.05. All statistical analysis were performed using GraphPad Prism 6
(GraphPad Software, La Jolla, CA, USA).
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